James D Griffin

发表

BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.

Christian Sillaber, Peter Valent, J. Griffin, 2002, Blood.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

Following the cytokine signaling pathway to leukemogenesis: a chronology.

Kendall A. Smith, J. Griffin, James D Griffin, 2008, The Journal of clinical investigation.

Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.

Pascal Furet, Guido Bold, Arghya Ray, 2008, Blood.

Acute myeloid leukemia and acute promyelocytic leukemia.

Bob Löwenberg, J. Griffin, M. Tallman, 2003, Hematology. American Society of Hematology. Education Program.

A Robust Error Model for iTRAQ Quantification Reveals Divergent Signaling between Oncogenic FLT3 Mutants in Acute Myeloid Leukemia*

Yi Zhang, Manor Askenazi, Jarrod A Marto, 2009, Molecular & Cellular Proteomics.

Interaction maps for kinase inhibitors

J. Griffin, James D Griffin, 2005, Nature Biotechnology.

The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors

Ravi Salgia, R. Salgia, J. Griffin, 1997, Oncogene.

Prediction of Resistance to Small Molecule FLT3 Inhibitors

Doriano Fabbro, Peter Marynen, Pascal Furet, 2004, Cancer Research.

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Donna Neuberg, Doriano Fabbro, Arghya Ray, 2005, Cancer cell.

Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.

Rob Pieters, Todd R Golub, John H Kersey, 2003, Cancer cell.

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

Doriano Fabbro, Paul Manley, D. Fabbro, 2002, Cancer cell.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

Doriano Fabbro, D. Fabbro, J. Griffin, 2005, Blood.

Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells

Arghya Ray, Jan Cools, Leigh Zawel, 2007, Molecular Cancer Therapeutics.

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Peter Marynen, Rafeul Alam, Jan Cools, 2003, The New England journal of medicine.

Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.

Stefan Fröhling, Benjamin L Ebert, Todd R Golub, 2007, Cancer cell.

The roles of FLT3 in hematopoiesis and leukemia.

J. Griffin, D. Gilliland, James D Griffin, 2002, Blood.